Fluorescent light links to metabolic and reproductive issues

12 11 2026
Fluorescent light links to metabolic and reproductive issues

A study on diurnal grass rats found that standard fluorescent office lighting weakens circadian rhythms and doubles the incidence of diabetic-range blood glucose compared to daylight conditions. Sperm motility was also cut by more than half in the fluorescent group. However, exposing the animals to just one hour of midday daylight restored their daily rhythms.

The finding suggests that indoor lighting is a biological exposure as significant as diet or exercise, but the results remain preliminary because they were observed in rodents. Researchers acknowledge that more work is needed to confirm these specific metabolic and reproductive effects apply to humans.

more: https://www.futurity.org/artificial-light-sleep-metabolism-3352612/?utm_source=rss&utm_medium=rss&utm_campaign=artificial-light-sleep-metabolism-3352612

my other side: ivo.blogspot.com





Pregnancy air pollution linked to teen lung function

11 11 2026
Pregnancy air pollution linked to teen lung function

A new Danish study tracked children from birth to age eighteen and found that exposure to just 2 micrograms more PM2.5 during pregnancy correlates with a two percent lower lung capacity at age six. This deficit does not disappear; these children show slower lung development continuing into adolescence.

The source notes that the association is observational, so it does not prove direct causation, though the consistency over time is striking. It highlights why societal efforts to clean the air matter more than individual parenting choices, as most local pollution often originates from outside national borders.

more: https://www.futurity.org/early-life-air-pollution-lung-function-3352672/?utm_source=rss&utm_medium=rss&utm_campaign=early-life-air-pollution-lung-function-3352672

my other side: ivo.blogspot.com





Earlier sleep timing linked to weight loss in prediabetes

9 11 2026
Earlier sleep timing linked to weight loss in prediabetes

A randomized trial found that going to bed earlier is associated with roughly 1.3 pounds of weight loss per hour of earlier sleep onset in adults with prediabetes. This effect was independent of total sleep duration, meaning the timing of sleep onset mattered more than how long participants slept. The mechanism likely involves reducing late-night eating and lowering stress hormones that drive appetite.

The core mechanism appears to be aligning food intake with the body's optimal metabolic window to avoid late-night eating when insulin sensitivity is lowest. However, the study did not show improved blood sugar levels, suggesting the weight loss benefit may be distinct from direct glycemic control in this specific cohort.

more: https://www.futurity.org/earlier-bedtime-weight-loss-prediabetes-3352242/?utm_source=rss&utm_medium=rss&utm_campaign=earlier-bedtime-weight-loss-prediabetes-3352242

my other side: ivo.blogspot.com





Heart scans outperform risk scores for statin decisions

8 11 2026
Heart scans outperform risk scores for statin decisions

The CorCal Outcomes trial found that using coronary artery calcium scans to guide statin prescriptions resulted in the same rate of major cardiovascular events as traditional risk assessments. However, the scan-based approach led to significantly fewer overall statin recommendations and much higher patient adherence to prescribed therapy.

This suggests that current risk calculators may miss many people who would benefit from treatment, while overtreat those who do not. The study does not prove the scan method is superior, but it highlights a gap in how we identify patients before their first heart attack.

more: https://www.sciencedaily.com/releases/2026/11/261105224604.htm

my other side: ivo.blogspot.com





High-dose flu shots linked to lower Alzheimer’s risk

8 11 2026
High-dose flu shots linked to lower Alzheimer's risk

A study of nearly 200,000 adults over 65 found that receiving the high-dose flu vaccine was associated with a 55% lower risk of developing Alzheimer's disease compared to the standard-dose shot. The high-dose formulation contains four times the antigen, which may trigger a more robust immune response in aging bodies.

It is an observational link, not proof of causation, so the immune benefit might be a proxy for other healthy behaviors. Still, if a routine annual shot offers unexpected neuroprotective value, it changes the cost-benefit calculation for seniors.

more: https://www.sciencedaily.com/releases/2026/11/261105224609.htm

my other side: ivo.blogspot.com





Coffee consumption and lower dementia risk

7 11 2026
Coffee consumption and lower dementia risk

A 43-year study of U.S. adults found that drinking two to three cups of caffeinated coffee daily is associated with a 57 percent lower incidence of dementia. The strongest benefits were seen in this specific range, with no additional protection observed from drinking more. Decaffeinated coffee did not show the same protective link, suggesting caffeine itself may play a role.

The association holds even among people with high genetic risk, indicating lifestyle factors can influence brain health independent of inheritance. However, this remains a correlation rather than proof of causation, as it is unclear if coffee prevents dementia or simply correlates with other healthy habits. Readers should treat this as an intriguing signal, not a prescription.

more: https://www.sciencedaily.com/releases/2026/11/261105224550.htm

my other side: ivo.blogspot.com





Rapamycin Improves Brain Blood Flow in APOE4 Carriers

6 11 2026
Rapamycin Improves Brain Blood Flow in APOE4 Carriers

A four‑week trial gave a low daily dose of rapamycin to adults aged 45‑65. Participants with the APOE4 variant showed measurable increases in cerebral blood flow, while non‑carriers did not. Women with APOE4 had the largest benefit, suggesting sex‑specific effects.

These data point to rapamycin as a candidate for early intervention in people genetically predisposed to Alzheimer’s, but the study did not test long‑term cognitive outcomes. The effect was limited to a small sample and short duration, and whether improved circulation translates to reduced disease risk remains unknown. Clinicians and patients should view these results as preliminary.

more: https://www.sciencedaily.com/releases/2026/11/261104084017.htm

my other side: ivo.blogspot.com





Kopdes clinics risk deepening healthcare deficit

6 11 2026
Kopdes clinics risk deepening healthcare deficit

A plan to upgrade 83,000 village cooperative clinics to serve BPJS patients ignores a current monthly deficit of 2 trillion rupiah. The model mandates two doctors per clinic despite a national ratio of only 0.76 per 1,000 people, creating a recruitment impossibility.

This likely poaches existing staff from puskesmas rather than adding capacity, leaving rural patients with fewer choices and longer queues. The fiscal logic is fragile given the lack of clear funding sources, making the expansion a potential fiscal burden rather than a solution.

more: https://theconversation.com/klinik-kopdes-merah-putih-layani-bpjs-tanpa-dokter-bukan-solusi-atas-kebutuhan-warga-desa-295868

my other side: ivo.blogspot.com





Kratom exposure surge and its opioid risks

4 11 2026
Kratom exposure surge and its opioid risks

Reports of kratom exposure to poison centers rose by 1,200 percent between 2015 and 2025. The substance binds to opioid receptors, producing pain relief and euphoria while carrying significant risks of addiction and withdrawal.

Mislabeling creates a hidden hazard, as users may unknowingly ingest potent compounds disguised as supplements. While deaths are linked to misuse, isolation of kratom’s specific role remains difficult due to polydrug involvement.

more: https://www.futurity.org/kratom-risks-regulation-3351682/?utm_source=rss&utm_medium=rss&utm_campaign=kratom-risks-regulation-3351682

my other side: ivo.blogspot.com





AI finds brain-specific alternative to Ozempic

4 11 2026
AI finds brain-specific alternative to Ozempic

Stanford researchers identified a molecule called BRP that targets the hypothalamus to suppress appetite. Unlike semaglutide, which acts on gut and pancreas receptors, this compound focuses on a specific brain region to reduce hunger and fat loss.

The AI-driven approach bypassed the guesswork of traditional mass spectrometry by analyzing gene sequences for specific enzyme cuts. It remains an early stage animal study, so human trials are still needed to confirm whether this theoretical precision eliminates common side effects like nausea or muscle loss.

more: https://www.sciencedaily.com/releases/2026/11/261104004909.htm

my other side: ivo.blogspot.com